Sarepta Therapeutics Inc SRPT

NAS: SRPT | ISIN: US8036071004   21:40
130,34 USD (-0,79%)
(-0,79%)   21:40
Grafiek Sarepta Therapeutics Inc Grafiek Sarepta Therapeutics Inc

Sarepta Therapeutics Inc in het nieuws

5 november 2023 · ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT · Persbericht

3 november 2023 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT · Persbericht

30 augustus 2023 · Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test · Persbericht

18 maart 2021 · Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration · Persbericht

15 maart 2021 · Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference · Persbericht

25 februari 2021 · Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 · Persbericht

24 februari 2021 · Sarepta Therapeutics to Present at Upcoming Investor Conferences · Persbericht

22 februari 2021 · Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021 · Persbericht

5 februari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT · Persbericht

4 februari 2021 · Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition · Persbericht

Profiel Sarepta Therapeutics Inc

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.sarepta.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

CEO: Douglas Ingram

Werknemers: 1.326

Aandelen Sarepta Therapeutics Inc

Beurswaarde: 12,42 miljard USD

Effecten: 94,52 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,71

Mijn selecties